| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/04/2012 | EP2400987A1 Bendamustine cyclopolysaccharide compositions |
| 01/04/2012 | EP2400986A1 Enhanced migraine treatments based on ghrelin mimetics |
| 01/04/2012 | EP2400985A2 Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor |
| 01/04/2012 | EP2400980A2 Visfatin therapeutic agents for the treatment of acne and other conditions |
| 01/04/2012 | EP2400974A2 Synthetic diblock copolypeptide hydrogels for use in the central nervous system |
| 01/04/2012 | EP2400970A1 Pde 1 inhibitors for ophthalmic disorders |
| 01/04/2012 | EP2400969A1 Method for treating pulmonary diseases using rho kinase inhibitor compounds |
| 01/04/2012 | EP2400968A1 Compositions, synthesis, and methods of utilizing arylpiperazine derivatives |
| 01/04/2012 | EP2400967A1 Treatment of dyskinesia related disorders |
| 01/04/2012 | EP2400966A1 Combination of a nucleoside polymerase inhibitor with a macrocyclic protease inhibitor and use thereof in the treatment of hepatitis c, liver fibrosis and impaired liver function |
| 01/04/2012 | EP2400965A1 Sigma( ) receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anticancer activity |
| 01/04/2012 | EP2400964A1 Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| 01/04/2012 | EP2400963A1 Compositions for use in cardioplegia comprising esmolol and adenosine |
| 01/04/2012 | EP2400962A1 Drug combinations containing pde4 inhibitors and nsaids |
| 01/04/2012 | EP2400961A1 Drug combinations containing pde4 inhibitors and nsaids |
| 01/04/2012 | EP2400960A1 Ceramide-analogous metabolites |
| 01/04/2012 | EP2400959A1 Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity |
| 01/04/2012 | EP2400958A1 Serine palmitoyltransferase inhibitors for preventing and delaying retinitis pigmentosa |
| 01/04/2012 | EP2400955A1 Methods of administering (4ar, 1oar)-i-n-propyl-i, 2,3,4a7 s1io7 ioa-octahydrobenzo ýg¨quinoline-6,7-diol and related compounds across the oral mucosa, the nasal mucosa or the skin and pharmaceutical compositions thereof |
| 01/04/2012 | EP2400953A1 Uses of nk receptor antagonists |
| 01/04/2012 | EP2400952A2 Composition of a liposomal gel containing hydrocortisone, its metabolites, precursors or mixtures thereof and the use thereof |
| 01/04/2012 | EP2400951A1 Topical foam composition |
| 01/04/2012 | EP2400950A1 Pharmaceutical formulations comprising 4-{(1r)-2- [(6-{2-[(2,6-dichlorobenzyl)oxy] ethoxy}hexyl)amino]-1-hydroxyethyl}-2- (hydroxymethyl)phenol |
| 01/04/2012 | EP2400851A1 Composition and drug delivery of bisphosphonates |
| 01/04/2012 | EP2400848A1 Crystalization of pharmaceutical compounds |
| 01/04/2012 | EP2400847A1 Specific diarylhydantoin and diarylthiohydantoin compounds |
| 01/04/2012 | EP2400846A1 Hepatitis c virus inhibitors |
| 01/04/2012 | EP2400845A1 Thienopyridine derivatives for the treatment and prevention of dengue virus infections |
| 01/04/2012 | EP2400843A1 Iminosugars and methods of treating arenaviral infections |
| 01/04/2012 | EP2400842A1 Otic compositions useful for the treatment of infections of the internal and external ear in mammals |
| 01/04/2012 | EP2400841A1 Oral care compositions for treating xerostomia |
| 01/04/2012 | EP2400840A1 Liquid statin formulations |
| 01/04/2012 | EP2400839A1 Prebiotic formulations and methods of use |
| 01/04/2012 | EP2400838A1 Narcotic emulsion formulations for treatment of cancer pain |
| 01/04/2012 | EP2334687B1 Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |
| 01/04/2012 | EP2310389B1 Heterocycles as protein kinase inhibitors |
| 01/04/2012 | EP2300482B1 ANNELLATED 4-(INDAZOLYL)-1,4-DIHYDROPYRIDINE DERIVATIVES AS c-Met MEDIATORS |
| 01/04/2012 | EP2297148B1 Novel derivatives of (bridged piperazinyl)-1-alcanone and use thereof as p75 inhibitors |
| 01/04/2012 | EP2297103B1 Hydroxyphenylsulfonamides as antiapoptotic bcl inhibitors |
| 01/04/2012 | EP2265582B1 Novel 3-aminoalkyl-1,3-dihydro-2h-indol-2-one derivatives, preparation thereof and therapeutic use thereof. |
| 01/04/2012 | EP2259801B1 Stable pharmaceutical compositions of carvedilol |
| 01/04/2012 | EP2220080B1 Heterocyclic derivatives as modulators of ion channels |
| 01/04/2012 | EP2164492B1 Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine for treating schizophrenia |
| 01/04/2012 | EP2155694B1 Triazinone and diazinone derivatives useful as hsp90 inhibitors |
| 01/04/2012 | EP2146989B1 Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases |
| 01/04/2012 | EP2092065B1 Antisense compounds |
| 01/04/2012 | EP2078026B1 Prodrug salts of 2, 4-pyrimidinediamine compounds and their uses |
| 01/04/2012 | EP2056829B1 Using pi3k and mek modulators in treatments of cancer |
| 01/04/2012 | EP2049502B1 2,4-substituted quinazolines as lipid kinase inhibitors |
| 01/04/2012 | EP2043637B1 Methods and medicaments for administration of ibuprofen |
| 01/04/2012 | EP1986645B1 Glucokinase activators |
| 01/04/2012 | EP1986620B1 Dextromethorphan for the treatment of acne |
| 01/04/2012 | EP1951254B1 [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto |
| 01/04/2012 | EP1928461B1 Pyrimidine compounds as serotonin receptor modulators |
| 01/04/2012 | EP1877366B1 Hydroxamic acid dervicatives as inhibitors of hdac enzymatic activity |
| 01/04/2012 | EP1858504B1 Carnitine-containing peritoneal dialysis solution having improved biocompatibility |
| 01/04/2012 | EP1830829B1 Sphingolipids in treatment and prevention of hepatic steatosis |
| 01/04/2012 | EP1827101B1 Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases |
| 01/04/2012 | EP1814878B1 Spiro-2, 4-pyrimidinediamine compounds and their uses |
| 01/04/2012 | EP1814596B1 Antisense antiviral compounds and methods for treating filovirus infection |
| 01/04/2012 | EP1812015B1 Methods for inhibition of nkt cells |
| 01/04/2012 | EP1793816B1 Compositions for treating amyloid associated diseases |
| 01/04/2012 | EP1781298B1 Pharmaceutical combinations containing benzoxazine for treating respiratory diseases |
| 01/04/2012 | EP1742639B1 Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
| 01/04/2012 | EP1735286B1 Tetrahydro-indazole cannabinoid modulators |
| 01/04/2012 | EP1671635B1 Noncrystalline antibacterial composition containing cefditoren pivoxil |
| 01/04/2012 | EP1638569B1 Use of brimonidine for preventing and reducing the severity of stress-associated conditions |
| 01/04/2012 | EP1620058B1 Composition for improving cognition and memory |
| 01/04/2012 | EP1562604B1 Prostaglandin compounds for the treatment of obesity |
| 01/04/2012 | EP1539149B1 Combinations of metabotropic glutamate receptor antagonists and their use in treating addictive disorders |
| 01/04/2012 | EP1494649B1 Nanoparticulate megestrol formulations |
| 01/04/2012 | EP1441720B1 Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system |
| 01/04/2012 | EP1422225B1 Benzoisoselenazole derivatives with anti-inflammation, antineoplastic and anti-thrombosis activity and their use |
| 01/04/2012 | EP1339663B1 Naphthalene derivatives |
| 01/04/2012 | CN1972921B 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors |
| 01/04/2012 | CN1954855B Eye preparation containing sodium hyaluronate for treating fundus macular degeneration and its preparation method |
| 01/04/2012 | CN1558765B Enantiomerically pure opioid diarylmethylpiperzine and methods of using same |
| 01/04/2012 | CN102307997A Treatment of sirtuin 1 (SIRT1) related disease by inhibition of natural antisense transcript to SIRT1 |
| 01/04/2012 | CN102307881A Tripolide C-ring derivatives as anticancer agents and immune modulators |
| 01/04/2012 | CN102307878A 3,6-disubstituted xanthylium salts |
| 01/04/2012 | CN102307877A Dihydroetorphines and their preparation |
| 01/04/2012 | CN102307876A Synthesis of morphine-6-glucuronide or one of the derivatives thereof |
| 01/04/2012 | CN102307875A Pyrrolopyrimidinyl axl kinase inhibitors |
| 01/04/2012 | CN102307874A Peripheral opioid receptor antagonists and uses thereof |
| 01/04/2012 | CN102307872A BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| 01/04/2012 | CN102307871A Isoindolinone and related analogs as sirtuin modulators |
| 01/04/2012 | CN102307870A Pyridyloxyindoles inhibitors of VEGF-R2 and use thereof for treatment of disease |
| 01/04/2012 | CN102307869A Aminopyrazine derivative and medicine |
| 01/04/2012 | CN102307868A Indole derivatives as anticancer agents |
| 01/04/2012 | CN102307867A Dihydroquinolinone derivatives |
| 01/04/2012 | CN102307863A Pyrimidine derivatives, horticultural insecticides comprising said derivatives and method of use thereof |
| 01/04/2012 | CN102307862A Compounds for treating cancer |
| 01/04/2012 | CN102307861A Phenylimidazole compounds |
| 01/04/2012 | CN102307860A GPR120 receptor agonists and uses thereof |
| 01/04/2012 | CN102307857A High penetration compositions and their applications |
| 01/04/2012 | CN102307853A Pyrrolidine derivatives as NK3 receptor antagonists |
| 01/04/2012 | CN102307852A Cyclic amine compounds |
| 01/04/2012 | CN102307847A Indanyl compounds |
| 01/04/2012 | CN102307842A Plant extracts from acronychia species and their use |
| 01/04/2012 | CN102307836A Compounds for use in the treatment of pain |